Category Archives: Proteins

Antibody Engineering and Therapeutics Conference

I was invited to speak at the Antibody Engineering and Therapeutics Conference (presenting mine and Matt’s recently published epitope profiling paper), in San Diego (December 12th – 16th). Unfortunately, the pandemic had other ideas so I decided not to travel but luckily the conference was hybrid. 

The conference included 1 day of pre-conference workshops and 4 days of presentations from academic and industry, with livestreaming of the initial keynotes (including one from Charlotte). Remaining talks were recorded and made available after the conference. I’ve highlighted a few of my favourite talks and conference themes, with links to papers where available.

Naturally, a lot of the presented research related to covid-19. I was speaking in the ‘Antibody Repertoires and Covid-19’ session, where there were interesting presentations from Professor Eline Luning Prak from the University of Pennsylvania and Elaine Chen from Vanderbilt University analysing antibody responses in covid-recovered individuals, and comparing vaccine responses in covid-recovered vs covid-naiive individuals. Other talks around SARS-CoV-2 vaccines included Dr Laura Walker from Adimab/Adagio Therapeutics comparing BCR repertoire responses to different types of vaccinations, and the effect of using different booster types.

Continue reading →

Targeted protein degradation phenotypic studies using HaloTag CRISPR/Cas9 endogenous target tagging and HaloPROTAC

Biologists currently have several options in their arsenal when it comes to gene silencing. if you want to completely vanquish the gene in question, you can use CRISPR to knock the gene out completely. This is a great way to completely eliminate the gene, and hence compare cell phenotypes with and without the gene, but it’s less good if the gene is essential and the cells won’t grow without it in the first place. 

Otherwise you can use RNA interference, where small pieces of RNA that complement the mRNA for that gene are introduced to the cell, with the overall effect of blocking transcription of that gene’s mRNA, hence silencing it. However, this method suffers from side effects and varying levels of gene knockdown efficiency. Moreover, it does not vanquish existing protein, it just stops more from being produced.

Continue reading →

AlphaFold 2 is here: what’s behind the structure prediction miracle

Nature has now released that AlphaFold 2 paper, after eight long months of waiting. The main text reports more or less what we have known for nearly a year, with some added tidbits, although it is accompanied by a painstaking description of the architecture in the supplementary information. Perhaps more importantly, the authors have released the entirety of the code, including all details to run the pipeline, on Github. And there is no small print this time: you can run inference on any protein (I’ve checked!).

Have you not heard the news? Let me refresh your memory. In November 2020, a team of AI scientists from Google DeepMind  indisputably won the 14th Critical Assessment of Structural Prediction competition, a biennial blind test where computational biologists try to predict the structure of several proteins whose structure has been determined experimentally but not publicly released. Their results were so astounding, and the problem so central to biology, that it took the entire world by surprise and left an entire discipline, computational biology, wondering what had just happened.

Continue reading →

A to Z of Alternative Antibody Formats: Next-Generation Therapeutics

Do you know your diabodies from your zybodies?

Antibodies are a highly important class of therapeutics used to treat a range of diseases. Given their success as therapeutics, a wide variety of alternative antibody formats have been developed – these are driving the next generation of antibody therapeutics.

To note, this is not an exhaustive list but rather intended to demonstrate the range of existing antibody formats.

Inspired by this article in The Guardian: “Rachel Roddy’s A-Z of pasta“

Figure 1. Alternative Antibody Formats
Many of these figures were adapted from Spiess et al., 2015. Additionally, some of these formats have multiple variations or further possible forms (e.g., trispecific antibodies) – in these cases, one example is given here.

A – Antibodies

Antibodies – a fitting place to start this post. Antibodies are proteins produced by our immune systems to detect and protect against foreign pathogens. The ability of antibodies to bind molecules strongly and specifically – properties essential to their role in our immune defence – also make them valuable candidates for therapeutics. Antibody therapies have been developed for the treatment of various diseases, including cancers and viruses, and form a market estimated at over $100 billion1.

Continue reading →

How fast can a protein fold?

A protein’s folding time is the time required for it to reach its unique folded state starting from its unfolded ensemble. Globular, cytosolic proteins can only attain their intended biological function once they have folded. This means that protein folding times, which typically exceed the timescales of enzymatic reactions that proteins carry out by several orders of magnitude, are critical to determining when proteins become functional. Many scientists have worked tirelessly over the years to measure protein folding times, determine their theoretical bounds, and understand how they fit into biology. Here, I focus on one of the more interesting questions to fall out of this field over the years: how fast can a protein fold? Note that this is a very different question than asking “how fast do proteins fold?”

Continue reading →

The Smallest Allosteric System

Allostery is still a badly understood but very general mechanism in the protein world. In principle, an allosteric event occurs when a ligand (small or big) binds to a certain site of a protein and something (activity or function) changes at a different, distant site. A well-known example would be G-protein-coupled receptors that transport such an allosteric signal even across a membrane. But it does not have to be that far apart. As part of the Protein Folding and Dynamics series, I have recently watched a talk by Peter Hamm (Zurich) who presented work on an allosteric system that I thought was very interesting because it was small and most importantly, controllable.

PDZ domains are peptide-binding domains, often part of multi-domain proteins. For the work presented the researchers used the PDZ3 domain which is a bit special and has an additional (third) C-terminal α-helix (α3-helix) which is packing to the other side of the binding pocket. Previous work (Petit et al. 2009) had shown that removal of the α3-helix had changed ligand affinity but not PDZ structure, major changes were of an entropic nature instead. Peter Hamm’s group linked an azobenzene-derived photoswitch to that α3-helix; in its cis configuration stabilizing the α3-helix and destabilising in trans (see Figure 1).

Figure 1: PDZ3 domain (purple) and photoswitch (red) have different affinities for the peptide ligand (green), depending on the photoswitch’s isomerisation state (and temperature). From Bozovic, O., Jankovic, B. & Hamm, P. Sensing the allosteric force. Nat Commun 11, 5841 (2020). https://doi.org/10.1038/s41467-020-19689-7
Continue reading →

Bioinformatics Hackathon Reflection

A week ago I participated in Copenhagen Bioinformatics Hackathon 2021, a hackathon focusing on machine learning and proteins, as a mentor for a challenge proposed by our group. The whole experience was fun, but I am also sitting here contemplating over a lot of things I wish I had done differently. For this blog text, I therefore want to highlight two changes which I believe would have greatly improved my challenge and which can hopefully also work as an inspiration for others presenting a hackathon challenge. 

Going into this event I had some experience from a few hackathons I had previously attended. Based on this, I wanted to create a challenge containing two parts. First, a simple task which everyone would be able to create a solution for, and second, a more challenging addition to the first task for more experienced participants. I decided to go with the challenge of predicting which heavy and light chains can form a pair, where the additional challenge was to try to visualize which residues were relevant for this interaction. Together with OAS containing a really nice positive dataset of paired chains, I thought this was going to be an amazing challenge, but as soon as the event began I started seeing the flaws of the challenge.

Continue reading →

The Coronavirus Antibody Database: 10 months on, 10x the data!

Back in May 2020, we released the Coronavirus Antibody Database (‘CoV-AbDab’) to capture molecular information on existing coronavirus-binding antibodies, and to track what we anticipated would be a boon of data on antibodies able to bind SARS-CoV-2. At the time, we had found around 300 relevant antibody sequences and a handful of solved crystal structures, most of which were characterised shortly after the SARS-CoV epidemic of 2003. We had no idea just how many SARS-CoV-2 binding antibody sequences would come to be released into the public domain…

10 months later (2nd March 2021), we now have tracked 2,673 coronavirus-binding antibodies, ~95% with full Fv sequence information and ~5% with solved structures. These datapoints originate from 100s of independent studies reported in either the academic literature or patent filings.

The entire contents CoV-AbDab database as of 2nd March 2021.
Continue reading →

Ribosome occupancy profiles are conserved between structurally and evolutionarily related yeast domains

Shameless plug for any OPIG blog readers to take a look at our recent publication in Bioinformatics. Consider giving it a read if the below summary grabs your attention.

Many proteins are now known to fold during their synthesis through the process known as co-translational folding. Translation is an inherently non-equilibrium process – one consequence of this fact is that the speed of translation can radically influence the ability of proteins to fold and function. In this paper we compare ribosome occupancy profiles between related domains in yeast to test the hypothesis that evolutionarily related proteins with similar native folds should tend to have similar translation speed profiles to preserve efficient co-translational folding. We find strong evidence in support of this hypothesis at the level of individual protein domains and across a set of 664 pairs of related domains for which we are able to compute high-quality ribosome occupancy profiles.

To find out more, view the Advance Article at Bioinformatics.

Miniproteins – small but mighty!

Proteins come in all shapes and sizes, ranging from thousands of amino acids in length to less than 20. However, smaller size does not correlate with reduced importance. Miniproteins, which are commonly defined as being less than 100 amino acids long, are receiving increased attention for their potential roles as pharmaceuticals. A recent paper by David Baker’s group put miniproteins into the spotlight, as the study authors were able to design miniproteins that bind the SARS-CoV-2 spike protein with as strong affinity as an antibody would – but in a tiny fraction of the size (Cao et al., 2020). These miniproteins are much cheaper to manufacture than antibodies (as they can be expressed in bacteria) and can be highly stable (with melting temperatures of >90º possible, meaning they can easily be stored at room temperature). The most promising miniprotein developed by the Baker group (LCB1) is currently undergoing testing to be used as a prophylactic nasal spray that provides protection against SARS-CoV-2 infection. These promising results – and the speed in which progress was made – brings the vast potential of miniproteins in healthcare to the fore.

Continue reading →